COST-EFFECTIVENESS ANALYSIS OF EGFR MUTATION TEST FOR NON-SMALL CELL LUNG CANCER IN CHINA
Author(s)
Jin G, Yang L
Peking University, Beijing, China
OBJECTIVES: To examine the cost-effectiveness of EGFR mutation testing in China, and make recommendations on whether ‘EGFR testing strategy’ is more appropriate than ‘no EGFR-testing strategy’. METHODS: A five-year Markov model was constructed to predict expected costs and outcomes for each strategy, in which three states including progression-free survival, progressive survival and death were taken into account RESULTS: The incremental cost and effectiveness of the ‘EGFR testing strategy’ compared to the ‘no EGFR-testing strategy’ was estimated to be approximately 32,383.83 yuan and 0.294 QALY per patient. The ICER was then calculated to be around per QALY gained. These results suggest that the ‘EGFR testing strategy’ is more cost-effective compared with the ‘no EGFR-testing strategy’ when 15,4098 yuan per QALY based on GDP in 2015 was considered an acceptable threshold. These results were supported by the sensitivity analyses. CONCLUSIONS: From the perspective of healthcare payer, the ICER of the ‘EGFR-testing strategy’ can be considered as a cost-effective therapy compared with the ‘no EGFR-testing strategy’ by the threshold of 154,098 yuan.
Conference/Value in Health Info
2017-05, ISPOR 2017, Boston, MA, USA
Value in Health, Vol. 20, No. 5 (May 2017)
Code
PMD66
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Oncology